High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab
Crossref DOI link: https://doi.org/10.1007/s00259-015-3175-6
Published Online: 2015-09-04
Published Print: 2016-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Weber, Tobias
Bötticher, Benedikt
Mier, Walter
Sauter, Max
Krämer, Susanne
Leotta, Karin
Keller, Armin
Schlegelmilch, Anne
Grosse-Hovest, Ludger
Jäger, Dirk
Haberkorn, Uwe
Arndt, Michaela A. E.
Krauss, Jürgen
Text and Data Mining valid from 2015-09-04